Our results suggest a possibility that simultaneous application of TGFBR2 agonist and hTERT inhibitors may be developed as a therapeutic strategy for treating cervical cancer, especially in the patients with TGFBR2low/hTERThigh expressions. The gene discussed is TGFBR2; the disease is cervical carcinoma.